GlassScriptPhysician profile
Neyssan Tebyani
NPI 1740245265
$7,123.30
in general payments reported to CMS, 2019-2025
25 companies · $534 in 2025
The $534 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $3,484 · 2021: $872 · 2022: $821 · 2023: $634 · 2024: $542 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597 · Education: $80.00 · Gift: $33.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.79 |
| Education | $80.00 |
| Gift | $33.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,566.07 | 2020-2023 | |
| Abbvie INC. | $1,249.66 | 2019-2025 | Botox, Lupron Depot, Alloderm |
| Astellas Pharma US INC | $641.21 | 2019-2022 | |
| Boston Scientific Corporation | $328.82 | 2021-2023 | Ams 700, Rezum Generator |
| Caldera Medical, INC | $251.72 | 2021-2022 | |
| Janssen Biotech, INC. | $193.58 | 2019-2025 | Erleada |
| Teleflex LLC | $169.08 | 2021-2025 | Barrigel, Urolift |
| Allergan, INC. | $130.98 | 2020-2022 | |
| Pfizer INC. | $113.04 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.64 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $51.73 | 2023-2025 | Gemtesa, Orgovyx |
| Accord Healthcare, INC. | $50.73 | 2024 | |
| Myovant Sciences INC. | $43.46 | 2021 | |
| Antares Pharma, INC. | $37.51 | 2024 | Xyosted |
| Telix Pharmaceuticals | $30.52 | 2025 | Illuccix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $26.68 | 2025 | Eligard |
| Novartis Pharmaceuticals Corporation | $26.16 | 2022 | |
| Bluewind Medical | $25.72 | 2024 | |
| Endo Pharmaceuticals INC. | $23.77 | 2023 | Xiaflex, Aveed |
| Calyxo, INC. | $16.67 | 2025 | Cvac Aspiration System |
| Urovant Sciences INC | $16.02 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $15.62 | 2019 | |
| Merck Sharp & Dohme LLC | $14.98 | 2025 | Keytruda |
| Dendreon Pharmaceuticals LLC | $13.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neyssan Tebyani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.